Pfizer Whistleblower Suit Alleges Sales Reps Had Targets For Rapamune Off-Label Uses
This article was originally published in The Pink Sheet Daily
Executive Summary
Former Wyeth sales reps also allege they were trained to avoid FDA personnel at medical meetings.
You may also be interested in...
Rapamune Off-Label Suit Prompts Congressional Investigation
House Oversight Committee is investigating allegations Wyeth promoted Rapamune for unapproved uses. Chairman Towns says he is concerned the drug was targeted to high-risk African-Americans; Pfizer says the drug is not contraindicated for this population.
Rapamune Off-Label Suit Prompts Congressional Investigation
House Oversight Committee is investigating allegations Wyeth promoted Rapamune for unapproved uses. Chairman Towns says he is concerned the drug was targeted to high-risk African-Americans; Pfizer says the drug is not contraindicated for this population.
DDMAC's Latest Exhibit Hall Citation Is Vectibix; Firms Try Multiple Ways To Avoid FDA At Trade Shows
Amgen rep's description of KRAS information as predictive of response to the colorectal cancer drug during a ASHP meeting draws a notice of violation from FDA.